The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.a

Left or biventricular dysfunction/failure

Publications

Camilli M, Viscovo M, Felici T, Maggio L, Ballacci F, Carella G, Bonanni A, Lamendola P, Tinti L, Di Renzo A, Coarelli G, Galli E, Liuzzo G, Burzotta F, Montone RA, Sorà F, Sica S, Hohaus S, Lanza GA, Crea F, Lombardo A, Minotti G

Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study.

Cardio-oncology (London, England) 2024 Mar 27;10 — 2024 Mar 27 — 18

Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K

Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management.

Diseases (Basel, Switzerland) 2021 Mar 17;9; — 2021 Mar 17